The sharp improvement in financials is non-recurring and tied to the Takeda license deal. Investors should focus on upcoming clinical milestones for rinvatercept in DMD and ALS as the next value drivers. The share repurchase significantly reduced cash, but runway remains sufficient into 2028.
Price Chart
Executive Summary
Keros Therapeutics reported a net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, driven primarily by $205.4 million in license revenue from Takeda. The company is advancing rinvatercept into a Phase 2 trial for Duchenne muscular dystrophy in Q2 2026 and plans regulatory engagement for an ALS trial. Cash reserves decreased to $287.4 million from $559.9 million, but the company expects this to fund operations into early 2028.
Key Financial Metrics
Key Facts
- Net income of $87.0 million in 2025 vs. $187.4 million net loss in 2024, driven by $205.4 million in license revenue from Takeda
- R&D expenses declined to $129.6 million in 2025 from $173.6 million in 2024 due to transition of elritercept R&D to Takeda
- Cash and cash equivalents dropped to $287.4 million as of Dec 31, 2025 from $559.9 million in 2024, primarily due to share repurchase and tender offer
- Company expects cash runway into first half of 2028
- Phase 2 trial for rinvatercept in DMD expected to start in Q2 2026; regulatory discussions for ALS trial planned in second half of 2026
- Board changes: Charles Newton appointed, Carl Gordon stepping down; Esther Cho promoted to Chief Legal Officer
Financial Impact
Revenue increased from $3.55M in 2024 to $244.06M in 2025, driven by $205.36M in license revenue. Net loss turned into net income of $87.0M. Cash decreased by $272.5M year-over-year.
Risk Factors
- Revenue surge is largely one-time license income; future revenue depends on clinical progress and partnerships
- Cash burn remains high on operating basis; future funding may require dilution or new partnerships
- Clinical development risk for rinvatercept in DMD and ALS is high given early-stage nature
- Loss of key personnel or delays in trial initiation could impact timeline and valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249712 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 23d ago | 8-K | $11.31 $11.04 | ▼ −2.39% | ▼ −2.05% | $11.17 (−1.24%) |
Aug 20, 2026 6w ago | Insider Cluster | $10.95 $11.23 | ▲ +2.56% | ▲ +1.44% | $11.17 (+2.01%) |
Aug 3, 2026 8w ago | 8-K | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Aug 3, 2026 8w ago | Press Release | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Jul 30, 2026 9w ago | 8-K | $10.07 $11.15 | ▲ +10.72% | ▲ +7.21% | $11.17 (+10.92%) |
Jul 22, 2026 10w ago | 8-K | $10.14 $10.22 | ▲ +0.79% | ▲ +0.31% | $11.17 (+10.16%) |
Jun 17, 2026 15w ago | Insider Cluster | $10.65 $10.41 | ▼ −2.25% | ▼ −0.59% | $11.17 (+4.88%) |
Jun 8, 2026 16w ago | Insider Cluster | $10.07 $10.24 | ▲ +1.69% | ▼ −0.72% | $11.17 (+10.92%) |
May 14, 2026 20w ago | 8-K | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
May 14, 2026 20w ago | Press Release | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access